This meeting took place in 2005

For a complete list of the meetings for the upcoming/current season,
see our meeting list, or search for a meeting.

Antibody-Based Therapeutics for Cancer (B5)

Organizer(s) Louis M. Weiner and Paul Carter

February 17—22, 2005

Hilton Santa Fe Historic Plaza Hotel • Santa Fe, NM USA

Abstract Deadline: Oct 18, 2004

Late Abstract Deadline:

Scholarship Deadline:

Early Registration Deadline: Dec 17, 2004

Sponsored by Genentech, Inc. and The Director's Fund

Summary of Meeting:Monoclonal antibodies have emerged as increasingly important therapeutic vehicles for the treatment of cancer and other human diseases. Selected un-conjugated antibodies can exert clinically meaningful anti-tumor effects in important cancers such as breast cancer and lymphoma. The mechanisms underlying these exciting results remain to be elucidated, but most likely include the induction of host immune responses and the perturbation of signaling through growth factor receptors. Antibody conjugates have been used to deliver toxic principles such as radioactive particles, chemotherapy agents and catalytic toxins with increasing success in defined clinical settings. Advances in antibody engineering have permitted the systematic evaluation of structural manipulation on targeting and efficacy. Antibodies with novel specificities can be isolated with increasing ease from naive and immunized phage display libraries. Major challenges in this rapidly evolving field include the development of improved means for identifying new functional targets for antibody perturbation.

Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

If your organization is interested in joining these entities in support of Keystone
Symposia, please contact:&nbspSarah Lavicka,
Director of Corporate Relations, Email: sarahl@keystonesymposia.org,Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.